Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. by Lenos, K, Grawenda, A, Lodder, K, Kuijjer, M, Teunisse, A, Repapi, E, Grochola, L, Bartel, F, Hogendoorn, P, Wuerl, P, Taubert, H, Cleton-Jansen, A, Bond, G, Jochemsen, A

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer by Lenos, K, Miedema, D, Lodestijn, S, Nijman, L, Van Den Bosch, T, Romero Ros, X, Lourenço, F, Lecca, M, Van Der Heijden, M, Van Neerven, S, Van Oort, A, Leveille, N, Adam, R, De Sousa E Melo, F, Otten, J, Veerman, P, Hypolite, G, Koens, L, Lyons, S, Stassi, G, Winton, D, Medema, J, Morrissey, E, Bijlsma, M, Vermeulen, L